1
|
Grenier C, Caillon A, Munier M, Grimaud L, Champin T, Toutain B, Fassot C, Blanc-Brude O, Loufrani L. Dual Role of Thrombospondin-1 in Flow-Induced Remodeling. Int J Mol Sci 2021; 22:12086. [PMID: 34769516 PMCID: PMC8584526 DOI: 10.3390/ijms222112086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 10/13/2021] [Accepted: 10/29/2021] [Indexed: 11/21/2022] Open
Abstract
(1) Background: Chronic increases in blood flow, as in cardiovascular diseases, induce outward arterial remodeling. Thrombospondin-1 (TSP-1) is known to interact with matrix proteins and immune cell-surface receptors, but its contribution to flow-mediated remodeling in the microcirculation remains unknown. (2) Methods: Mesenteric arteries were ligated in vivo to generate high- (HF) and normal-flow (NF) arteries in wild-type (WT) and TSP-1-deleted mice (TSP-1-/-). After 7 days, arteries were isolated and studied ex vivo. (3) Results: Chronic increases in blood flow induced outward remodeling in WT mice (increasing diameter from 221 ± 10 to 280 ± 10 µm with 75 mmHg intraluminal pressure) without significant effect in TSP-1-/- (296 ± 18 to 303 ± 14 µm), neutropenic or adoptive bone marrow transfer mice. Four days after ligature, pro inflammatory gene expression levels (CD68, Cox2, Gp91phox, p47phox and p22phox) increased in WT HF arteries but not in TSP-1-/- mice. Perivascular neutrophil accumulation at day 4 was significantly lower in TSP-1-/- than in WT mice. (4) Conclusions: TSP-1 origin is important; indeed, circulating TSP-1 participates in vasodilation, whereas both circulating and tissue TSP-1 are involved in arterial wall thickness and diameter expansion.
Collapse
Affiliation(s)
- Céline Grenier
- UMR CNRS 6015, 49100 Angers, France; (C.G.); (A.C.); (M.M.); (L.G.); (T.C.); (B.T.); (C.F.)
- INSERM U1083, 49100 Angers, France
- MITOVASC Institute, University of Angers, 49100 Angers, France
| | - Antoine Caillon
- UMR CNRS 6015, 49100 Angers, France; (C.G.); (A.C.); (M.M.); (L.G.); (T.C.); (B.T.); (C.F.)
- INSERM U1083, 49100 Angers, France
- MITOVASC Institute, University of Angers, 49100 Angers, France
| | - Mathilde Munier
- UMR CNRS 6015, 49100 Angers, France; (C.G.); (A.C.); (M.M.); (L.G.); (T.C.); (B.T.); (C.F.)
- INSERM U1083, 49100 Angers, France
- MITOVASC Institute, University of Angers, 49100 Angers, France
| | - Linda Grimaud
- UMR CNRS 6015, 49100 Angers, France; (C.G.); (A.C.); (M.M.); (L.G.); (T.C.); (B.T.); (C.F.)
- INSERM U1083, 49100 Angers, France
- MITOVASC Institute, University of Angers, 49100 Angers, France
| | - Tristan Champin
- UMR CNRS 6015, 49100 Angers, France; (C.G.); (A.C.); (M.M.); (L.G.); (T.C.); (B.T.); (C.F.)
- INSERM U1083, 49100 Angers, France
- MITOVASC Institute, University of Angers, 49100 Angers, France
| | - Bertrand Toutain
- UMR CNRS 6015, 49100 Angers, France; (C.G.); (A.C.); (M.M.); (L.G.); (T.C.); (B.T.); (C.F.)
- INSERM U1083, 49100 Angers, France
- MITOVASC Institute, University of Angers, 49100 Angers, France
| | - Céline Fassot
- UMR CNRS 6015, 49100 Angers, France; (C.G.); (A.C.); (M.M.); (L.G.); (T.C.); (B.T.); (C.F.)
- INSERM U1083, 49100 Angers, France
- MITOVASC Institute, University of Angers, 49100 Angers, France
| | | | - Laurent Loufrani
- UMR CNRS 6015, 49100 Angers, France; (C.G.); (A.C.); (M.M.); (L.G.); (T.C.); (B.T.); (C.F.)
- INSERM U1083, 49100 Angers, France
- MITOVASC Institute, University of Angers, 49100 Angers, France
| |
Collapse
|
2
|
Robert P, Nguyen PMC, Richard A, Grenier C, Chevrollier A, Munier M, Grimaud L, Proux C, Champin T, Lelièvre E, Sarzi E, Vessières E, Henni S, Prunier D, Reynier P, Lenaers G, Fassot C, Henrion D, Loufrani L. Protective role of the mitochondrial fusion protein OPA1 in hypertension. FASEB J 2021; 35:e21678. [PMID: 34133045 DOI: 10.1096/fj.202000238rrr] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Revised: 05/04/2021] [Accepted: 05/04/2021] [Indexed: 11/11/2022]
Abstract
Hypertension is associated with excessive reactive oxygen species (ROS) production in vascular cells. Mitochondria undergo fusion and fission, a process playing a role in mitochondrial function. OPA1 is essential for mitochondrial fusion. Loss of OPA1 is associated with ROS production and cell dysfunction. We hypothesized that mitochondria fusion could reduce oxidative stress that defect in fusion would exacerbate hypertension. Using (a) Opa1 haploinsufficiency in isolated resistance arteries from Opa1+/- mice, (b) primary vascular cells from Opa1+/- mice, and (c) RNA interference experiments with siRNA against Opa1 in vascular cells, we investigated the role of mitochondria fusion in hypertension. In hypertension, Opa1 haploinsufficiency induced altered mitochondrial cristae structure both in vascular smooth muscle and endothelial cells but did not modify protein level of long and short forms of OPA1. In addition, we demonstrated an increase of mitochondrial ROS production, associated with a decrease of superoxide dismutase 1 protein expression. We also observed an increase of apoptosis in vascular cells and a decreased VSMCs proliferation. Blood pressure, vascular contractility, as well as endothelium-dependent and -independent relaxation were similar in Opa1+/- , WT, L-NAME-treated Opa1+/- and WT mice. Nevertheless, chronic NO-synthase inhibition with L-NAME induced a greater hypertension in Opa1+/- than in WT mice without compensatory arterial wall hypertrophy. This was associated with a stronger reduction in endothelium-dependent relaxation due to excessive ROS production. Our results highlight the protective role of mitochondria fusion in the vasculature during hypertension by limiting mitochondria ROS production.
Collapse
Affiliation(s)
- Pauline Robert
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| | - Phuc Minh Chau Nguyen
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| | - Alexis Richard
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| | - Céline Grenier
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| | - Arnaud Chevrollier
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| | - Mathilde Munier
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| | - Linda Grimaud
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| | - Coralyne Proux
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| | - Tristan Champin
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| | - Eric Lelièvre
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
| | - Emmanuelle Sarzi
- Institute for Neurosciences of Montpellier-INSERM U1051, Montpellier, France
| | - Emilie Vessières
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| | - Samir Henni
- University Hospital (CHU) of Angers, Angers, France
| | - Delphine Prunier
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
- University Hospital (CHU) of Angers, Angers, France
| | - Pascal Reynier
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
- University Hospital (CHU) of Angers, Angers, France
| | - Guys Lenaers
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
- University Hospital (CHU) of Angers, Angers, France
| | - Céline Fassot
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| | - Daniel Henrion
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
- University Hospital (CHU) of Angers, Angers, France
| | - Laurent Loufrani
- MITOVASC Institute and CARFI Facility, University of Angers, Angers, France
- UMR CNRS 6015, Angers, France
- INSERM U1083, Angers, France
| |
Collapse
|
3
|
Payen C, Guillot A, Paillat L, Fothi A, Dib A, Bourreau J, Schmitt F, Loufrani L, Aranyi T, Henrion D, Munier M, Fassot C. Pathophysiological adaptations of resistance arteries in rat offspring exposed in utero to maternal obesity is associated with sex-specific epigenetic alterations. Int J Obes (Lond) 2021; 45:1074-1085. [PMID: 33637953 DOI: 10.1038/s41366-021-00777-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 12/10/2020] [Accepted: 01/27/2021] [Indexed: 12/21/2022]
Abstract
BACKGROUND/OBJECTIVES Maternal obesity impacts vascular functions linked to metabolic disorders in offspring, leading to cardiovascular diseases during adulthood. Even if the relation between prenatal conditioning of cardiovascular diseases by maternal obesity and vascular function begins to be documented, little is known about resistance arteries. They are of particular interest because of their specific role in the regulation of local blood flow. Then our study aims to determine if maternal obesity can directly program fetal vascular dysfunction of resistance arteries, independently of metabolic disorders. METHODS With a model of rats exposed in utero to mild maternal diet-induced obesity (OMO), we investigated third-order mesenteric arteries of 4-month old rats in absence of metabolic disorders. The methylation profile of these vessels was determined by reduced representation bisulfite sequencing (RRBS). Vascular structure and reactivity were investigated using histomorphometry analysis and wire-myography. The metabolic function was evaluated by insulin and glucose tolerance tests, plasma lipid profile, and adipose tissue analysis. RESULTS At 4 months of age, small mesenteric arteries of OMO presented specific epigenetic modulations of matrix metalloproteinases (MMPs), collagens, and potassium channels genes in association with an outward remodeling and perturbations in the endothelium-dependent vasodilation pathways (greater contribution of EDHFs pathway in OMO males compared to control rats, and greater implication of PGI2 in OMO females compared to control rats). These vascular modifications were detected in absence of metabolic disorders. CONCLUSIONS Our study reports a specific methylation profile of resistance arteries associated with vascular remodeling and vasodilation balance perturbations in offspring exposed in utero to maternal obesity, in absence of metabolic dysfunctions.
Collapse
Affiliation(s)
- Cyrielle Payen
- UMR CNRS 6015, INSERM U1083, Mitovasc Laboratory, University of Angers, Angers, France
| | - Abigaëlle Guillot
- UMR CNRS 6015, INSERM U1083, Mitovasc Laboratory, University of Angers, Angers, France
| | - Lily Paillat
- UMR CNRS 6015, INSERM U1083, Mitovasc Laboratory, University of Angers, Angers, France
| | - Abel Fothi
- Institute of Enzymology, Research Center for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
| | - Abdallah Dib
- UMR CNRS 6015, INSERM U1083, Mitovasc Laboratory, University of Angers, Angers, France
| | - Jennifer Bourreau
- UMR CNRS 6015, INSERM U1083, Mitovasc Laboratory, University of Angers, Angers, France
| | - Françoise Schmitt
- UPRES EA 3859, HIFIH laboratory, Angers, France.,University Hospital of Angers, Angers, France
| | - Laurent Loufrani
- UMR CNRS 6015, INSERM U1083, Mitovasc Laboratory, University of Angers, Angers, France
| | - Tamas Aranyi
- Institute of Enzymology, Research Center for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.,Department of Molecular Biology, Institute of Biochemistry and Molecular Biology, Semmelweis University, Budapest, Hungary
| | - Daniel Henrion
- UMR CNRS 6015, INSERM U1083, Mitovasc Laboratory, University of Angers, Angers, France.,University Hospital of Angers, Angers, France.,CARFI (Cardiovascular Function In Vitro) Facility, Angers, France
| | - Mathilde Munier
- UMR CNRS 6015, INSERM U1083, Mitovasc Laboratory, University of Angers, Angers, France.,University Hospital of Angers, Angers, France.,Reference Center for Rare Disease of Thyroid and Hormone Receptors, University Hospital Angers, Angers, France
| | - Céline Fassot
- UMR CNRS 6015, INSERM U1083, Mitovasc Laboratory, University of Angers, Angers, France.
| |
Collapse
|
4
|
Guivarc'h E, Favre J, Guihot AL, Vessières E, Grimaud L, Proux C, Rivron J, Barbelivien A, Fassot C, Briet M, Lenfant F, Fontaine C, Loufrani L, Arnal JF, Henrion D. Nuclear Activation Function 2 Estrogen Receptor α Attenuates Arterial and Renal Alterations Due to Aging and Hypertension in Female Mice. J Am Heart Assoc 2020; 9:e013895. [PMID: 32102616 PMCID: PMC7335584 DOI: 10.1161/jaha.119.013895] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Background The cardiovascular protective effects of estrogens in premenopausal women depend mainly on estrogen receptor α (ERα). ERα activates nuclear gene transcription regulation and membrane‐initiated signaling. The latter plays a key role in estrogen‐dependent activation of endothelial NO synthase. The goal of the present work was to determine the respective roles of the 2 ERα activities in endothelial function and cardiac and kidney damage in young and old female mice with hypertension, which is a major risk factor in postmenopausal women. Methods and Results Five‐ and 18‐month‐old female mice lacking either ERα (ERα−/−), the nuclear activating function AF2 of ERα (AF2°), or membrane‐located ERα (C451A) were treated with angiotensin II (0.5 mg/kg per day) for 1 month. Systolic blood pressure, left ventricle weight, vascular reactivity, and kidney function were then assessed. Angiotensin II increased systolic blood pressure, ventricle weight, and vascular contractility in ERα−/− and AF2° mice more than in wild‐type and C451A mice, independent of age. In both the aorta and mesenteric resistance arteries, angiotensin II and aging reduced endothelium‐dependent relaxation in all groups, but this effect was more pronounced in ERα−/− and AF2° than in the wild‐type and C451A mice. Kidney inflammation and oxidative stress, as well as blood urea and creatinine levels, were also more pronounced in old hypertensive ERα−/− and AF2° than in old hypertensive wild‐type and C451A mice. Conclusions The nuclear ERα‐AF2 dependent function attenuates angiotensin II–dependent hypertension and protects target organs in aging mice, whereas membrane ERα signaling does not seem to play a role.
Collapse
Affiliation(s)
- Emmanuel Guivarc'h
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France
| | - Julie Favre
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France
| | - Anne-Laure Guihot
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France
| | - Emilie Vessières
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France
| | - Linda Grimaud
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France
| | - Coralyne Proux
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France
| | - Jordan Rivron
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France
| | - Agnès Barbelivien
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France
| | - Céline Fassot
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France
| | - Marie Briet
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France.,University Hospital of Angers Angers France
| | - Françoise Lenfant
- Institut des Maladies Métaboliques et Cardiovasculaires Université de Toulouse 3 UMR INSERM 1048 Toulouse France
| | - Coralie Fontaine
- Institut des Maladies Métaboliques et Cardiovasculaires Université de Toulouse 3 UMR INSERM 1048 Toulouse France
| | - Laurent Loufrani
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France
| | - Jean-François Arnal
- Institut des Maladies Métaboliques et Cardiovasculaires Université de Toulouse 3 UMR INSERM 1048 Toulouse France
| | - Daniel Henrion
- MITOVASC Institute and CARFI Facility INSERM U1083 CNRS UMR 6015 Angers University Angers France.,University Hospital of Angers Angers France
| |
Collapse
|
5
|
Belizna C, Pregnolato F, Abad S, Alijotas-Reig J, Amital H, Amoura Z, Andreoli L, Andres E, Aouba A, Apras Bilgen S, Arnaud L, Bienvenu B, Bitsadze V, Blanco P, Blank M, Borghi MO, Caligaro A, Candrea E, Canti V, Chiche L, Chretien JM, Cohen Tervaert JW, Damian L, Delross T, Dernis E, Devreese K, Djokovic A, Esteve-Valverde E, Favaro M, Fassot C, Ferrer-Oliveras R, Godon A, Hamidou M, Hasan M, Henrion D, Imbert B, Jeandel PY, Jeannin P, Jego P, Jourde-Chiche N, Khizroeva J, Lambotte O, Landron C, Latino JO, Lazaro E, de Leeuw K, Le Gallou T, Kiliç L, Limper M, Loufrani L, Lubin R, Magy-Bertrand N, Mahe G, Makatsariya A, Martin T, Muchardt C, Nagy G, Omarjee L, Van Paasen P, Pernod G, Perrinet F, Pïres Rosa G, Pistorius MA, Ruffatti A, Said F, Saulnier P, Sene D, Sentilhes L, Shovman O, Sibilia J, Sinescu C, Stanisavljevic N, Stojanovich L, Tam LS, Tincani A, Tollis F, Udry S, Ungeheuer MN, Versini M, Cervera R, Meroni PL. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmun Rev 2018; 17:1153-1168. [PMID: 30316994 DOI: 10.1016/j.autrev.2018.05.012] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2018] [Accepted: 05/25/2018] [Indexed: 02/09/2023]
Abstract
The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.
Collapse
Affiliation(s)
- Cristina Belizna
- Vascular and Coagulation Department, University Hospital Angers, Angers, France; MITOVASC institute and CARFI facility, UMR CNRS 6015, INSERM U1083, University of Angers, Angers, France.
| | - Francesca Pregnolato
- Istituto Auxologico Italiano, IRCCS, Laboratory of Immunorheumatology, Milan, Italy
| | - Sebastien Abad
- Department of Internal Medicine, Hospital Avicenne, Publique - Hôpitaux de Paris, University Paris 13, Bobigny, France
| | - Jaume Alijotas-Reig
- Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Medicine, Universitat Autonòma, Barcelona, Spain
| | - Howard Amital
- The Zabludowicz Center for Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Zahir Amoura
- Internal Medicine Department 2, Pitié-Salpêtrière Hospital, French National Centre for Rare Systemic Diseases, AP-HP, Paris, France; Paris VI University, UPMC, Sorbonne Universities, Paris, France
| | - Laura Andreoli
- Rheumatology and Clinical Immunology Unit, University of Brescia, Brescia, Italy
| | - Emmanuel Andres
- Internal Medicine Department, University Hospital Strasbourg, Strasbourg, France
| | - Achile Aouba
- Department of Internal Medicine, Caen University Hospital, Caen, France; University of Normandy, Caen, France
| | | | - Laurent Arnaud
- Rheumatology Department, University Hospital Strasbourg, Strasbourg, France
| | - Boris Bienvenu
- Department of Internal Medicine, Saint Joseph Hospital, Marseille, France
| | - Viktoria Bitsadze
- Department of Obstetrics and Gynecology, I.M. Sechenow First Moscow State Medical University, Moscow, Russia
| | - Patrick Blanco
- ImmunoConcEpT, CNRS-UMR 5164, University Bordeaux, Bordeaux, France; FHU ACRONIM, Bordeaux University Hospital, Place Amélie Raba Léon, 33076 Bordeaux, France
| | - Miri Blank
- The Zabludowicz Center for Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Maria Orietta Borghi
- Istituto Auxologico Italiano, IRCCS, Laboratory of Immunorheumatology, Milan, Italy
| | - Antonia Caligaro
- Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy
| | - Elisabeta Candrea
- Department of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Valentina Canti
- Immunology, Rheumatology, Allergology and Rare Disease-IRCCS San Raffaele Hospital, Laboratory of Autoimmunity and vascular inflammation San Raffaele, Milan, Italy
| | - Laurent Chiche
- Department of Internal Medicine and Infectious Disease, Hôpital européen Marseille, Marseille, France
| | | | - Jan Willem Cohen Tervaert
- Nephrology Department, Maastricht University, Maastricht, the Netherlands; Rheumatology Department, Kaye Edmonton Clinic University of Alberta, Edmonton, Canada
| | - Laura Damian
- Department of Rheumatology, County Emergency Hospital Cluj-Napoca, Cluj-Napoca, Romania
| | - Teresa Delross
- Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy
| | | | - Katrien Devreese
- Coagulation Laboratory, Department of Clinical Biology, Immunology and Microbiology, Ghent University Hospital, Ghent, Belgium
| | - Aleksandra Djokovic
- Scientific Research Department, Internal Medicine-Rheumatology Bezhanijska Kosa, University Medical Center, Belgrade University, Belgrade, Serbia
| | | | - Maria Favaro
- Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy
| | - Céline Fassot
- MITOVASC institute and CARFI facility, UMR CNRS 6015, INSERM U1083, University of Angers, Angers, France
| | - Raquel Ferrer-Oliveras
- Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Alban Godon
- Departement of hematology et immunology, University Hospital Angers, Angers, France
| | - Mohamed Hamidou
- Department of Internal Medicine, University Hospital Nantes, Nantes, France
| | - Milena Hasan
- Cytometry and Biomarkers Unit of Technology and Service, Center for Translational Science, Institut Pasteur, 28, Rue Doct Roux, 75015 Paris, France
| | - Daniel Henrion
- MITOVASC institute and CARFI facility, UMR CNRS 6015, INSERM U1083, University of Angers, Angers, France
| | - Bernard Imbert
- Vascular Medicine Department, Grenoble University Hospital, Grenoble, France
| | - Pierre Yves Jeandel
- Department of Internal Medicine, Archet-1 Hospital, University of Nice-Sophia-Antipolis, 151 Route de Saint Antoine de Ginestière, 06202 Nice, France
| | - Pascale Jeannin
- Departement of hematology et immunology, University Hospital Angers, Angers, France
| | - Patrick Jego
- Department of Internal Medicine, University Hospital Rennes, Rennes, France
| | - Noemie Jourde-Chiche
- INSERM, UMR-S 1076, VRCM, Aix-Marseille University, Marseille, France; Centre de Néphrologie et Transplantation Rénale, AP-HM, Marseille, France
| | - Jamilya Khizroeva
- Department of Obstetrics and Gynecology, I.M. Sechenow First Moscow State Medical University, Moscow, Russia
| | - Olivier Lambotte
- Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie clinique, F-94275 Le Kremlin-Bicêtre, France; UMR 1184, Université Paris Sud, F-94276 Le Kremlin-Bicêtre, France; INSERM, U1184, Immunology of Viral Infections and Autoimmune Diseases, F-94276 Le Kremlin-Bicêtre, France; CEA, DSV/iMETI, IDMIT, F-92265 Fontenay-aux-Roses, France
| | - Cédric Landron
- Department of Internal Medicine, University Hospital Poitiers, Poitiers, France
| | - Jose Omar Latino
- Autoimmune and thrombophilic disorders Department, Hospital Carlos G. Durand, Buenos Aires, Argentina
| | - Estibaliz Lazaro
- Department of Internal Medicine, Haut-Lévêque Hospital, 33604 Pessac, France
| | - Karina de Leeuw
- Department of Internal Medicine, Division of Clinical Immunology, University Hospital Groningen, Groningen, the Netherlands
| | - Thomas Le Gallou
- Department of Internal Medicine, University Hospital Rennes, Rennes, France
| | - Levent Kiliç
- Internal Medicine Department, Hacettepe University, Ankara, Turkey
| | - Maarten Limper
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Laurent Loufrani
- MITOVASC institute and CARFI facility, UMR CNRS 6015, INSERM U1083, University of Angers, Angers, France
| | - Romain Lubin
- MITOVASC institute and CARFI facility, UMR CNRS 6015, INSERM U1083, University of Angers, Angers, France
| | - Nadine Magy-Bertrand
- Department of Internal Medicine, University Hospital Jean Minjoz, Besançon, France
| | - Guillaume Mahe
- Vascular Medicine Department, University Hospital Rennes, Rennes, France; CHU Rennes, INSERM, CIC 1414, University Rennes, F-35000 Rennes, France
| | - Alexander Makatsariya
- Department of Obstetrics and Gynecology, I.M. Sechenow First Moscow State Medical University, Moscow, Russia
| | - Thierry Martin
- Clinical Immunology Department, University Hospital Strasbourg, Strasbourg, France
| | - Christian Muchardt
- CM Unit of Epigenetic Regulation, Department of Developmental and Stem Cell Biology UMR3738 CNRS, Pasteur Institute, Paris, France
| | - Gyorgy Nagy
- Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary; Department of Rheumatology, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
| | - Loukman Omarjee
- Vascular Medicine Department, University Hospital Rennes, Rennes, France; CHU Rennes, INSERM, CIC 1414, University Rennes, F-35000 Rennes, France
| | - Pieter Van Paasen
- Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Gilles Pernod
- InnoVTE: French Investigation Network on Venous Thromboembolique Disease, Grenoble-Alps University, France; Informatique, Mathématiques et Applications (IMAG) Unité Mixte de Recherche (UMR), 5525/Themas, Centre National de Recherche Scientifique (CNRS)/Techniques de l'Ingénieurie Médicale et de la Complexité (TIMC), Grenoble, France
| | | | - Gilberto Pïres Rosa
- Internal Medicine Sao Joao Hospital, Alameda Prof Hernani Monteiro Vila Nova de Gaia, 4200-319 Porto, Portugal
| | | | - Amelia Ruffatti
- Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy
| | - Fatma Said
- Internal Medicine Department, University Hospital La Rabta, Tunis, Tunisia
| | - Patrick Saulnier
- Research Department Unit, University Hospital Angers, Angers, France
| | - Damien Sene
- Department of Internal Medicine, Lariboisière Hospital, Paris Diderot University, Paris, France
| | - Loic Sentilhes
- Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France
| | - Ova Shovman
- The Zabludowicz Center for Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
| | - Jean Sibilia
- Rheumatology Department, University Hospital Strasbourg, Strasbourg, France
| | - Crina Sinescu
- Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Natasa Stanisavljevic
- Scientific Research Department, Internal Medicine-Rheumatology Bezhanijska Kosa, University Medical Center, Belgrade University, Belgrade, Serbia
| | - Ljudmila Stojanovich
- Scientific Research Department, Internal Medicine-Rheumatology Bezhanijska Kosa, University Medical Center, Belgrade University, Belgrade, Serbia
| | - Lai Shan Tam
- Department of Medicine and Therapeutics, and Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, China
| | - Angela Tincani
- Rheumatology and Clinical Immunology Unit, University of Brescia, Brescia, Italy
| | | | - Sebastian Udry
- Autoimmune and thrombophilic disorders Department, Hospital Carlos G. Durand, Buenos Aires, Argentina
| | - Marie Noelle Ungeheuer
- Clinical Investigation and Acces to Bioresources Department, Institut Pasteur, 28, Rue Doct Roux, 75015 Paris, France
| | | | - Ricard Cervera
- Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain
| | - Pier Luigi Meroni
- Istituto Auxologico Italiano, IRCCS, Laboratory of Immunorheumatology, Milan, Italy
| |
Collapse
|
6
|
Garnier AS, El Ali S, Henrion D, Guardiola P, Fassot C, Pietrement C, Briet M. La carbamylation des protéines induit un remodelage des artères de gros et de petit calibre. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Belizna C, Stojanovich L, Cohen-Tervaert JW, Fassot C, Henrion D, Loufrani L, Nagy G, Muchardt C, Hasan M, Ungeheuer MN, Arnaud L, Alijotas-Reig J, Esteve-Valverde E, Nicoletti F, Saulnier P, Godon A, Reynier P, Chrétien JM, Damian L, Omarjee L, Mahé G, Pistorius MA, Meroni PL, Devreese K. Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities? Autoimmun Rev 2018; 17:739-745. [PMID: 29885541 DOI: 10.1016/j.autrev.2018.01.027] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2018] [Accepted: 01/12/2018] [Indexed: 11/25/2022]
Abstract
Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.
Collapse
Affiliation(s)
- Cristina Belizna
- Vascular and Coagulation Department, University Hospital Angers, 4 rue Larrey, 49000 Angers, France; MITOVASC Institute and CARFI Facility, University of Angers, UMR CNRS 6015, INSERM U1083, rue Haute de Reculée, 49045 Angers, France..
| | - Ljudmila Stojanovich
- Scientific Research Department, Internal Medicine-Rheumatology, Bezhanijska Kosa, University Medical Center, Belgrade University, Belgrade 11080, Serbia
| | - Jan Willem Cohen-Tervaert
- Internal Medicine and Immunology Department, Maastricht University, P Debyelaan 25, 6229 HX Maastricht, The Netherlands; Rheumatology Department, Kaye Edmonton Clinic University of Alberta, 116 St. and 85 Ave., Edmonton, AB T6G 2R3, Canada
| | - Céline Fassot
- MITOVASC Institute and CARFI Facility, University of Angers, UMR CNRS 6015, INSERM U1083, rue Haute de Reculée, 49045 Angers, France
| | - Daniel Henrion
- MITOVASC Institute and CARFI Facility, University of Angers, UMR CNRS 6015, INSERM U1083, rue Haute de Reculée, 49045 Angers, France
| | - Laurent Loufrani
- MITOVASC Institute and CARFI Facility, University of Angers, UMR CNRS 6015, INSERM U1083, rue Haute de Reculée, 49045 Angers, France
| | - Gyorgy Nagy
- 3rd Department of Internal Medicine, Rheumatology Division, Buda Hospital of the Hospitaller Order of Saint John of God, H-1023 Budapest, P.O.B. 98, Hungary; Semmelweis University, Department of Genetics, Cell- and Immunobiology, Buda Hospital of the Hospitalier Order of Saint John of God, 1089 Budapest, Nagyvárad tér 4, Hungary
| | - Christian Muchardt
- Unit of Epigenetic Regulation, Department of Developmental and Stem Cell Biology, UMR3738 CNRS, Institut Pasteur, 28, Rue Doct Roux, 75015 Paris, France
| | - Milena Hasan
- Cytometry and Biomarkers Unit of Technology and Service, Center for Translational Science, Institut Pasteur, 28, Rue Doct Roux, 75015 Paris, France
| | - Marie Noelle Ungeheuer
- Clinical Investigation and Acces to Bioresources Department, Institut Pasteur, 28, Rue Doct Roux, 75015 Paris, France
| | - Laurent Arnaud
- Rheumatology Department, University Hospital Strasbourg, 1, Place de l'Hôpital, 67091 Strasbourg, France
| | - Jaume Alijotas-Reig
- Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Department of Medicine, Universitat Autonòma, Plaza Civica, 08193 Barcelona, Spain
| | - Enrique Esteve-Valverde
- Internal Medicine Althaia Healthcare Network of Manresa, Calle Pau 44, 08243 Manresa, Barcelona, Spain
| | - Ferdinando Nicoletti
- Department of Biomedicine and Biotechnology, University of Catania, Universita' Square, 2, 95131 Catania, Italy
| | - Patrick Saulnier
- Research Department Unit University Hospital Angers, 4 rue Larrey, 49000 Angers, France
| | - Alban Godon
- Departement of hematology et immunology University Hospital Angers, 4 rue Larrey, 49000 Angers, France
| | - Pascal Reynier
- MITOVASC Institute and CARFI Facility, University of Angers, UMR CNRS 6015, INSERM U1083, rue Haute de Reculée, 49045 Angers, France.; Department of Biochemistry and Genetics University Hospital Angers, 4 rue Larrey, 49000 Angers, France
| | - Jean Marie Chrétien
- Research Department Unit University Hospital Angers, 4 rue Larrey, 49000 Angers, France
| | - Laura Damian
- Department of Rheumatology, County Emergency Hospital Cluj-Napoca, Str. Clinicilor nr.3-5, Cod Postal 400006 Cluj-Napoca, Romania
| | - Loukman Omarjee
- Vascular Medicine Department, University Hospital Rennes, 16, Boulevard de Bulgarie, 35203 Rennes, France; University Rennes, CHU Rennes, INSERM, CIC 1414, 2, rue Henri Le Guilloux, 35000 Rennes Cedex 9, France
| | - Guillaume Mahé
- Vascular Medicine Department, University Hospital Rennes, 16, Boulevard de Bulgarie, 35203 Rennes, France; University Rennes, CHU Rennes, INSERM, CIC 1414, 2, rue Henri Le Guilloux, 35000 Rennes Cedex 9, France
| | - Marc Antoine Pistorius
- Vascular Medicine Department, University Hospital Nantes, 1, Place Alexis Ricordeau, 44093 Nantes, France
| | - Pier Luigi Meroni
- Clinical Immunology and Rhumatology Research Department Auxologico Institute Milan, IRCCS, Via G. Spagnoletto, 3, 20149 Milan, Italy
| | - Katrien Devreese
- Coagulation Laboratory, Department of Clinical Biology, Immunology and Microbiology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
| |
Collapse
|
8
|
Garnier AS, El Ali S, Henrion D, Fassot C, Pietrement C, Briet M. FP528PROTEIN CARBAMYLATION INDUCES LARGE AND SMALL ARTERY REMODELING AND STIFFENING. Nephrol Dial Transplant 2018. [DOI: 10.1093/ndt/gfy104.fp528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | - Daniel Henrion
- Laboratoire MitoVasc, INSERM U1083, CNRS UMR 6214, Université d'Angers, Angers, France
| | - Céline Fassot
- Laboratoire MitoVasc, INSERM U1083, CNRS UMR 6214, Université d'Angers, Angers, France
| | - Christine Pietrement
- Laboratoire de biochimie médicale et biologie moléculaire, UMR CNRS/URCA 7369, Université de Reims, Reims, France
| | | |
Collapse
|
9
|
Dib A, Payen C, Bourreau J, Munier M, Grimaud L, Fajloun Z, Loufrani L, Henrion D, Fassot C. In Utero Exposure to Maternal Diabetes Is Associated With Early Abnormal Vascular Structure in Offspring. Front Physiol 2018; 9:350. [PMID: 29670546 PMCID: PMC5893798 DOI: 10.3389/fphys.2018.00350] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Accepted: 03/20/2018] [Indexed: 11/13/2022] Open
Abstract
Aim/hypothesis:In utero exposure to maternal diabetes increases the risk of developing hypertension and cardiovascular disorders during adulthood. We have previously shown that this is associated with changes in vascular tone in favor of a vasoconstrictor profile, which is involved in the development of hypertension. This excessive constrictor tone has also a strong impact on vascular structure. Our objective was to study the impact of in utero exposure to maternal diabetes on vascular structure and remodeling induced by chronic changes in hemodynamic parameters. Methods and Results: We used an animal model of rats exposed in utero to maternal hyperglycemia (DMO), which developed hypertension at 6 months of age. At a pre-hypertensive stage (3 months of age), we observed deep structural modifications of the vascular wall without any hemodynamic perturbations. Indeed, in basal conditions, resistance arteries of DMO rats are smaller than those of control mother offspring (CMO) rats; in addition, large arteries like thoracic aorta of DMO rats have an increase of smooth muscle cell attachments to elastic lamellae. In an isolated perfused kidney, we also observed a leftward shift of the flow/pressure relationship, suggesting a rise in renal peripheral vascular resistance in DMO compared to CMO rats. In this context, we studied vascular remodeling in response to reduced blood flow by in vivo mesenteric arteries ligation. In DMO rats, inward remodeling induced by a chronic reduction in blood flow (1 or 3 weeks after ligation) did not occur by contrast to CMO rats in which arterial diameter decreased from 428 ± 17 μm to 331 ± 20 μm (at 125 mmHg, p = 0.001). In these animals, the transglutaminase 2 (TG2) pathway, essential for inward remodeling development in case of flow perturbations, was not activated in low-flow (LF) mesenteric arteries. Finally, in old hypertensive DMO rats (18 months of age), we were not able to detect a pressure-induced remodeling in thoracic aorta. Conclusions: Our results demonstrate for the first time that in utero exposure to maternal diabetes induces deep changes in the vascular structure. Indeed, the early narrowing of the microvasculature and the structural modifications of conductance arteries could be a pre-emptive adaptation to fetal programming of hypertension.
Collapse
Affiliation(s)
- Abdallah Dib
- UMR Centre National de la Recherche Scientifique 6015, INSERM U1083, MITOVASC, University of Angers, Angers, France
| | - Cyrielle Payen
- UMR Centre National de la Recherche Scientifique 6015, INSERM U1083, MITOVASC, University of Angers, Angers, France
| | - Jennifer Bourreau
- UMR Centre National de la Recherche Scientifique 6015, INSERM U1083, MITOVASC, University of Angers, Angers, France
| | - Mathilde Munier
- UMR Centre National de la Recherche Scientifique 6015, INSERM U1083, MITOVASC, University of Angers, Angers, France.,University Hospital of Angers, Angers, France.,Reference Center for Rare Disease of Thyroid and Hormone Receptors, University Hospital Angers, Angers, France
| | - Linda Grimaud
- UMR Centre National de la Recherche Scientifique 6015, INSERM U1083, MITOVASC, University of Angers, Angers, France
| | - Ziad Fajloun
- Faculty of Sciences III, Azm Center for Research in Biotechnology and Its Applications, Doctoral School of Science and Technology, Lebanese University, Tripoli, Lebanon
| | - Laurent Loufrani
- UMR Centre National de la Recherche Scientifique 6015, INSERM U1083, MITOVASC, University of Angers, Angers, France.,University Hospital of Angers, Angers, France
| | - Daniel Henrion
- UMR Centre National de la Recherche Scientifique 6015, INSERM U1083, MITOVASC, University of Angers, Angers, France.,University Hospital of Angers, Angers, France
| | - Céline Fassot
- UMR Centre National de la Recherche Scientifique 6015, INSERM U1083, MITOVASC, University of Angers, Angers, France
| |
Collapse
|
10
|
Mshaik R, Tchatchat L, Roy J, Guihot A, Vessiers E, Barbelivien A, Fassot C, Loufrani L, Custaud M, Henrion D. The angiotensin II type 2 receptor promotes perivascular adipose tissue-dependent dilation in type 2 diabetic female mice and contraction in healthy mice. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
11
|
Freidja ML, Vessières E, Toutain B, Guihot AL, Custaud MA, Loufrani L, Fassot C, Henrion D. AGEs breaking and antioxidant treatment improves endothelium-dependent dilation without effect on flow-mediated remodeling of resistance arteries in old Zucker diabetic rats. Cardiovasc Diabetol 2014; 13:55. [PMID: 24581152 PMCID: PMC3944955 DOI: 10.1186/1475-2840-13-55] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2014] [Accepted: 02/26/2014] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND A chronic increase in blood flow in resistance arteries is associated with increased lumen diameter (outward remodeling) and improved endothelium (NO)-mediated relaxation. Flow-mediated remodeling of resistance arteries is essential for revascularization in ischemic diseases. Nevertheless, it is impaired in 12 to 24-month old rats and in young Zucker Diabetic Fatty (ZDF) rats due to advanced glycation end products (AGEs) and oxidative stress. As type 2 diabetes occurs preferentially in older subjects we investigated flow-mediated remodeling and the effect of the AGEs breaker ALT-711 associated or not to the antioxidant TEMPOL in one-year old lean (LZ) and ZDF rats. METHODS Mesenteric resistance arteries were exposed to high (HF) or normal blood flow (NF) in vivo. They were collected after 2 weeks for in vitro analysis. RESULTS In LZ rats, diameter expansion did not occur despite a significant increase in blood flow in HF arteries. Nevertheless, endothelium-mediated relaxation was higher in HF than in NF arteries. ALT-711, alone or in combination with TEMPOL, restored outward remodeling in HF arteries in association with AGEs reduction. TEMPOL alone had no effect. ALT-711, TEMPOL or the combination of the 2 drugs did not significantly affect endothelium-mediated relaxation in HF and NF arteries.In ZDF rats, diameter did not increase despite the increase in blood flow and endothelium-mediated relaxation was further decreased in HF arteries in association with AGEs accumulation and excessive oxidative stress. In both NF and HF arteries, endothelium-mediated relaxation was lower in ZDF than in LZ rats. ALT-711, TEMPOL or their combination did not improve remodeling (diameter equivalent in HF and NF arteries). In parallel, they did not reduce AGEs level and did not improve MMPs activity. Nevertheless, ALT-711 and TEMPOL partly improved endothelium-mediated relaxation through a reduction of oxidative stress and the association of ALT-711 and TEMPOL fully restored relaxation to the level found in LZ rats. CONCLUSIONS ALT-711 did not improve outward remodeling in mature ZDF rats but it reduced oxidative stress and consequently improved endothelium-dependent relaxation. In mature LZ rats, ALT-711 improved outward remodeling and reduced AGEs level. Consequently, AGEs breaking is differently useful in ageing whether it is associated with diabetes or not.
Collapse
|
12
|
Lagrange J, Li Z, Fassot C, Bourhim M, Louis H, Nguyen Dinh Cat A, Parlakian A, Wahl D, Lacolley P, Jaisser F, Regnault V. Endothelial mineralocorticoid receptor activation enhances endothelial protein C receptor and decreases vascular thrombosis in mice. FASEB J 2014; 28:2062-72. [PMID: 24451386 DOI: 10.1096/fj.13-238188] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Previous studies have shown that aldosterone, which activates the mineralocorticoid receptor (MR), promotes thrombosis in animal models. Our objective was to determine whether MR activation/expression in the vascular endothelium could modify thrombotic risk in vivo and to examine thrombin generation at the surface of aortic endothelial cells (HAECs). MR was conditionally overexpressed in vivo in vascular endothelial cells in mice (MR-EC mice) or stimulated with aldosterone in HAECs. Thrombosis after ferric chloride injury was delayed in MR-EC mice compared with controls as well as in wild-type FVB/NRj mice treated with aldosterone (60 μg/kg/d for 21 d). Thrombin generation in platelet-poor plasma did not differ between MR-EC mice and controls. In MR-EC mice, aortic endothelial cell protein C receptor (EPCR) expression was increased. Aldosterone (10(-8) M) attenuated thrombin generation at the surface of cultured HAECs, and this effect was associated with up-regulation of expression of EPCR, which promotes formation of activated protein C. Aldosterone increases EPCR expression via a transcriptional mechanism involving interaction of MR with the specificity protein 1 site. These findings demonstrate that MR activation acts on endothelial cells to protect against thrombosis in physiological conditions and that MR-mediated EPCR overexpression drives this antithrombotic property through enhancing protein C activation.
Collapse
Affiliation(s)
- Jérémy Lagrange
- 2INSERM U1116, Faculté de Médecine, 9 Avenue de la Forêt de Haye, 54500 Vandoeuvre-les-Nancy, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Habbout A, Guenancia C, Lorin J, Rigal E, Fassot C, Rochette L, Vergely C. Postnatal overfeeding causes early shifts in gene expression in the heart and long-term alterations in cardiometabolic and oxidative parameters. PLoS One 2013; 8:e56981. [PMID: 23468899 PMCID: PMC3582632 DOI: 10.1371/journal.pone.0056981] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2012] [Accepted: 01/16/2013] [Indexed: 01/24/2023] Open
Abstract
Background Postnatal overfeeding (OF) in rodents induces a permanent moderate increase in body weight in adulthood. However, the repercussions of postnatal OF on cardiac gene expression, cardiac metabolism and nitro-oxidative stress are less well known. Methodology/Principal Findings Immediately after birth, litters of C57BL/6 mice were either maintained at 10 (normal-fed group, NF), or reduced to 3 in order to induce OF. At weaning, mice of both groups received a standard diet. The cardiac gene expression profile was determined at weaning and cardiac metabolism and oxidative stress were assessed at 7 months. The cardiac expression of several genes, including members of the extracellular matrix and apelin pathway, was modified in juvenile OF mice. In adult mice, OF led to an increase in body weight (+30%) and to significant increases in plasma cholesterol, insulin and leptin levels. Myocardial oxidative stress, SOD and catalase activity and mRNA expression were increased in OF mice. In vivo, diastolic and systolic blood pressures were significantly higher and LV shortening and ejection fraction were decreased in OF mice. Ex vivo, after 30 min of ischemia, hearts isolated from OF mice showed lower functional recovery and larger infarct size (31% vs. 54%, p<0.05). Increases in collagen deposition and expression/activity of matrix-metalloproteinase-2 were observed in adult OF mouse hearts. Moreover, an increase in the expression of SOCS-3 and a decrease in STAT-3 phosphorylation were observed in ventricular tissues from OF mice. Conclusions/Significance Our study emphasizes that over-nutrition during the immediate postnatal period in mice leads to early changes in cardiac gene expression, which may permanently modify the heart’s structural organization and metabolism and could contribute to a greater susceptibility to myocardial ischemia-reperfusion injury.
Collapse
Affiliation(s)
- Ahmed Habbout
- Inserm UMR866, Laboratoire de Physiopathologie et Pharmacologie Cardio-Métaboliques (LPPCM), Faculties of Medicine and Pharmacy, University of Burgundy, Dijon, France
| | | | | | | | | | | | | |
Collapse
|
14
|
Retailleau K, Toutain B, Galmiche G, Fassot C, Sharif-Naeini R, Kauffenstein G, Mericskay M, Duprat F, Grimaud L, Merot J, Lardeux A, Pizard A, Baudrie V, Jeunemaitre X, Feil R, Göthert JR, Lacolley P, Henrion D, Li Z, Loufrani L. Selective Involvement of Serum Response Factor in Pressure-Induced Myogenic Tone in Resistance Arteries. Arterioscler Thromb Vasc Biol 2013; 33:339-46. [DOI: 10.1161/atvbaha.112.300708] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
In resistance arteries, diameter adjustment in response to pressure changes depends on the vascular cytoskeleton integrity. Serum response factor (SRF) is a dispensable transcription factor for cellular growth, but its role remains unknown in resistance arteries. We hypothesized that SRF is required for appropriate microvascular contraction.
Methods and Results—
We used mice in which SRF was specifically deleted in smooth muscle or endothelial cells, and their control. Myogenic tone and pharmacological contraction was determined in resistance arteries. mRNA and protein expression were assessed by quantitative real-time PCR (qRT-PCR) and Western blot. Actin polymerization was determined by confocal microscopy. Stress-activated channel activity was measured by patch clamp. Myogenic tone developing in response to pressure was dramatically decreased by SRF deletion (5.9±2.3%) compared with control (16.3±3.2%). This defect was accompanied by decreases in actin polymerization, filamin A, myosin light chain kinase and myosin light chain expression level, and stress-activated channel activity and sensitivity in response to pressure. Contractions induced by phenylephrine or U46619 were not modified, despite a higher sensitivity to p38 blockade; this highlights a compensatory pathway, allowing normal receptor-dependent contraction.
Conclusion—
This study shows for the first time that SRF has a major part to play in the control of local blood flow via its central role in pressure-induced myogenic tone in resistance arteries.
Collapse
Affiliation(s)
- Kevin Retailleau
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Bertrand Toutain
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Guillaume Galmiche
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Céline Fassot
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Reza Sharif-Naeini
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Gilles Kauffenstein
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Mathias Mericskay
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Fabrice Duprat
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Linda Grimaud
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Jean Merot
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Aurelie Lardeux
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Anne Pizard
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Véronique Baudrie
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Xavier Jeunemaitre
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Robert Feil
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Joachim R. Göthert
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Patrick Lacolley
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Daniel Henrion
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Zhenlin Li
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| | - Laurent Loufrani
- From the CNRS UMR-6214, INSERM U1083, Université d’Angers, PRES LUNAM, Angers, France (K.R., B.T., C.F., G.K., L.G., D.H., L.L.); CHU Angers, France (D.H., L.L.); Université Pierre & Marie Curie, Paris, France (G.G., M.M., Z.L.); IPMC-CNRS, Valbonne, France (R.S.-N., F.D.); INSERM 915, Nantes, France (J.M., A.L.); INSERM 961, Vandoeuvre les Nancy, France (A.P., P.L.); INSERM 970, Paris–Centre de Recherche Cardiovasculaire (PARCC), Faculty of Medicine, Université Paris Descartes, PRES Sorbonne
| |
Collapse
|
15
|
Vessières E, Freidja ML, Loufrani L, Fassot C, Henrion D. Flow (shear stress)-mediated remodeling of resistance arteries in diabetes. Vascul Pharmacol 2012; 57:173-8. [DOI: 10.1016/j.vph.2012.03.006] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2011] [Revised: 03/18/2012] [Accepted: 03/23/2012] [Indexed: 10/28/2022]
|
16
|
Freidja ML, Tarhouni K, Toutain B, Fassot C, Loufrani L, Henrion D. The AGE-breaker ALT-711 restores high blood flow-dependent remodeling in mesenteric resistance arteries in a rat model of type 2 diabetes. Diabetes 2012; 61:1562-72. [PMID: 22415880 PMCID: PMC3357287 DOI: 10.2337/db11-0750] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Flow-mediated remodeling of resistance arteries is essential for revascularization in ischemic diseases, but this is impaired in diabetes. We hypothesized that breaking advanced glycation end product (AGE) cross-links could improve remodeling in mesenteric resistance arteries in Zucker diabetic fatty (ZDF) rats compared with lean Zucker (LZ) rats. Arteries, exposed to high (HF) or normal (NF) blood flow after alternate arterial ligation in vivo, were collected after 2 weeks. In LZ rats, HF artery diameter was larger than for NF vessels, but this was not the case in ZDF rats. Endothelium-mediated dilation in ZDF rats, which was lower than in LZ rats, was further decreased in HF arteries. Treatment of rats with the AGE-breaker 4,5-dimethyl-3-phenacylthiazolium chloride (ALT-711) (3 mg/kg/day; 3 weeks) reversed diabetes-induced impairment of HF-dependent remodeling. ALT-711 also improved endothelium nitric oxide-dependent relaxation in mesenteric resistance arteries. Reactive oxygen species reduction restored relaxation in ZDF rats but not in LZ or ALT-711-treated rats. AGEs were reduced in ALT-711-treated ZDF rats compared with ZDF rats. Metalloproteinase activity, necessary for HF-dependent remodeling, was reduced in ZDF rats compared with LZ rats and restored by ALT-711. Thus, targeting AGE cross-links may provide a therapeutic potential for overcoming microvascular complications in ischemic disorders occurring in diabetes.
Collapse
|
17
|
Griol-Charhbili V, Fassot C, Messaoudi S, Perret C, Agrapart V, Jaisser F. Epidermal Growth Factor Receptor Mediates the Vascular Dysfunction But Not the Remodeling Induced by Aldosterone/Salt. Hypertension 2011; 57:238-44. [DOI: 10.1161/hypertensionaha.110.153619] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Pathophysiological aldosterone (aldo)/mineralocorticoid receptor signaling has a major impact on the cardiovascular system, resulting in hypertension and vascular remodeling. Mineralocorticoids induce endothelial dysfunction, decreasing vasorelaxation in response to acetylcholine and increasing the response to vasoconstrictors. Activation of the epidermal growth factor receptor (EGFR) is thought to mediate the vascular effects of aldo, but this has yet to be demonstrated in vivo. In this study, we analyzed the molecular and functional vascular consequences of aldo-salt challenge in the waved 2 mouse, a genetic model with a partial loss of EGFR tyrosine kinase activity. Deficient EGFR activity is associated with global oxidative stress and endothelial dysfunction. A decrease in EGFR activity did not affect the arterial wall remodeling process induced by aldo-salt. By contrast, normal EGFR activity was required for the aldo-induced enhancement of phenylephrine- and angiotensin II–mediated vasoconstriction. In conclusion, this in vivo study demonstrates that EGFR plays a key role in aldosterone-mediated vascular reactivity.
Collapse
Affiliation(s)
- Violaine Griol-Charhbili
- From the Institut National de la Santé et de la Recherche Médicale, U872, Centre de Recherche des Cordeliers, Paris, France; Pierre et Marie Curie University, Paris, France
| | - Céline Fassot
- From the Institut National de la Santé et de la Recherche Médicale, U872, Centre de Recherche des Cordeliers, Paris, France; Pierre et Marie Curie University, Paris, France
| | - Smail Messaoudi
- From the Institut National de la Santé et de la Recherche Médicale, U872, Centre de Recherche des Cordeliers, Paris, France; Pierre et Marie Curie University, Paris, France
| | - Claudine Perret
- From the Institut National de la Santé et de la Recherche Médicale, U872, Centre de Recherche des Cordeliers, Paris, France; Pierre et Marie Curie University, Paris, France
| | - Vincent Agrapart
- From the Institut National de la Santé et de la Recherche Médicale, U872, Centre de Recherche des Cordeliers, Paris, France; Pierre et Marie Curie University, Paris, France
| | - Frederic Jaisser
- From the Institut National de la Santé et de la Recherche Médicale, U872, Centre de Recherche des Cordeliers, Paris, France; Pierre et Marie Curie University, Paris, France
| |
Collapse
|
18
|
Duong Van Huyen JP, Vessières E, Perret C, Troise A, Prince S, Guihot AL, Barbry P, Henrion D, Bruneval P, Laurent S, Lelièvre-Pégorier M, Fassot C. In utero exposure to maternal diabetes impairs vascular expression of prostacyclin receptor in rat offspring. Diabetes 2010; 59:2597-602. [PMID: 20622163 PMCID: PMC3279527 DOI: 10.2337/db10-0311] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
OBJECTIVE To evaluate modifications of arterial structure, gene expression, and function in our model of rats exposed to maternal diabetes. RESEARCH DESIGN AND METHODS Morphometric analyses of elastic vessels structure and determination of thoracic aortic gene expression profile with oligonucleotide chips (Agilent, G4130, 22k) were performed before the onset of established hypertension (3 months). RESULTS Arterial parameters of in situ fixed thoracic aorta were not significantly different between control mother offspring and diabetic mother offspring (DMO). The aortic gene expression profile of DMO is characterized by modifications of several members of the arachidonic acid metabolism including a twofold underexpression of prostacyclin receptor, which could contribute to decreased vasodilatation. This was confirmed by ex vivo experiments on isolated aortic rings. Pharmacological studies on conscious rats showed that systolic blood pressure decline in response to a PGI(2) analog was impaired in DMO rats. CONCLUSIONS These results suggest an abnormal vascular fetal programming of prostacyclin receptor in rats exposed in utero to maternal hyperglycemia that is associated with impaired vasodilatation and may be involved in the pathophysiology of hypertension in this model.
Collapse
Affiliation(s)
- Jean-Paul Duong Van Huyen
- NSERM U872, Centre de Recherche des Cordeliers, Universite's Pierre et Marie Curie et Paris-Descartes, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Marc Y, Bodineau L, Frugiere A, Inguimbert N, Fassot C, Roques BP, Llorens-Cortes C. K004 Orally active aminopeptidase a inhibitors reduce blood pressure by blocking the brain renin-angiotensin system activity: a new strategy for the treatment of hypertension. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72407-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Nehiri T, Duong Van Huyen JP, Viltard M, Fassot C, Heudes D, Freund N, Deschênes G, Houillier P, Bruneval P, Lelièvre-Pégorier M. Exposure to maternal diabetes induces salt-sensitive hypertension and impairs renal function in adult rat offspring. Diabetes 2008; 57:2167-75. [PMID: 18443204 PMCID: PMC2494671 DOI: 10.2337/db07-0780] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
OBJECTIVE Epidemiological and experimental studies have led to the hypothesis of fetal origin of adult diseases, suggesting that some adult diseases might be determined before birth by altered fetal development. We have previously demonstrated in the rat that in utero exposure to maternal diabetes impairs renal development leading to a reduction in nephron number. Little is known on the long-term consequences of in utero exposure to maternal diabetes. The aim of the study was to assess, in the rat, long-term effects of in utero exposure to maternal diabetes on blood pressure and renal function in adulthood. RESEARCH DESIGN AND METHODS Diabetes was induced in Sprague-Dawley pregnant rats by streptozotocin on day 0 of gestation. Systolic blood pressure, plasma renin activity, and renal function were measured in the offspring from 1 to 18 months of age. High-salt diet experiments were performed at the prehypertensive stage, and the abundance of tubular sodium transporters was evaluated by Western blot analysis. Kidney tissues were processed for histopathology and glomerular computer-assisted histomorphometry. RESULTS AND CONCLUSIONS We demonstrated that in utero exposure to maternal diabetes induces a salt-sensitive hypertension in the offspring associated with a decrease in renal function in adulthood. High-salt diet experiments show an alteration of renal sodium handling that may be explained by a fetal reprogramming of tubular functions in association or as a result of the inborn nephron deficit induced by in utero exposure to maternal diabetes.
Collapse
Affiliation(s)
- Touria Nehiri
- Institut National de la Santé et de la Recherche Médicale, Unite Mixte de Recherche S872, Centre de Recherche des Cordeliers, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Bodineau L, Frugière A, Marc Y, Inguimbert N, Fassot C, Balavoine F, Roques B, Llorens-Cortes C. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 2008; 51:1318-25. [PMID: 18362226 DOI: 10.1161/hypertensionaha.107.098772] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Overactivity of the brain renin-angiotensin system has been implicated in the development and maintenance of hypertension. We reported previously that angiotensin II is converted to angiotensin III by aminopeptidase A in the mouse brain. We then used specific and selective aminopeptidase A inhibitors to show that angiotensin III is one of the main effector peptides of the brain renin-angiotensin system, exerting tonic stimulatory control over blood pressure in hypertensive rats. Aminopeptidase A, the enzyme generating brain angiotensin III, thus represents a potential candidate central nervous system target for the treatment of hypertension. Given this possible clinical use of aminopeptidase A inhibitors, it was, therefore, important to investigate their pharmacological activity after oral administration. We investigated RB150, a dimer of the selective aminopeptidase A inhibitor, EC33, generated by creating a disulfide bond. This chemical modification allows prodrug to cross the blood-brain barrier when administered by systemic route. Oral administration of RB150 in conscious DOCA-salt rats inhibited brain aminopeptidase A activity, resulting in values similar to those obtained with the brains of normotensive rats, demonstrating the central bioavailability of RB150. Oral RB150 treatment resulted in a marked dose-dependent reduction in blood pressure in DOCA-salt but not in normotensive rats, with an ED(50) in the 1-mg/kg range, achieved in <2 hours and lasting for several hours. This treatment also significantly decreased plasma arginine-vasopressin levels and increased diuresis, which may participate to the blood pressure decrease by reducing the size of fluid compartment. Thus, RB150 may be the prototype of a new class of centrally active antihypertensive agents.
Collapse
|
22
|
Iturrioz X, El Messari S, De Mota N, Fassot C, Alvear-Perez R, Maigret B, Llorens-Cortes C. [Functional dissociation between apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure]. Arch Mal Coeur Vaiss 2007; 100:704-708. [PMID: 17928781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Apelin is a peptide involved in the regulation of body fluid homeostasis and cardiovascular functions, that was recently isolated as the endogenous ligand for the human orphan APJ receptor, a G protein-coupled receptor which shares 31% amino-acid sequence identity with the angiotensin II type 1 receptor. The predominant molecular forms of apelin naturally occuring in vivo are apelin 36, apelin 17 (K17F) and the pyroglutamyl form of apelin 13 (pE13F). We investigated the structure-activity relationships of apelin at the rat apelin receptor, tagged at its C-terminal end with enhanced green fluorescent protein and stably expressed in CHO cells. We compared the abilities of N- and C-terminal deleted fragments of K17F (KFRRQRPRLSHKGPMPF) to bind with high affinity to the apelin receptor, to inhibit cAMP production and to induce apelin receptor internalization. The first five N-terminal and the last two C-terminal amino acids of K17F were not essential for apelin binding or cAMP response. In contrast, deletion of the arginine in position 6 drastically decreased binding and cAMP response. The full-length sequence of K17F was the most potent inducer of apelin receptor internalization because successive N-terminal amino-acid deletions progressively reduced internalization and the removal of a single amino acid, the phenylalanine in position 17 at the C-terminus of K17F abolished this process. Thus, K16P binds with high affinity to the apelin receptor and strongly inhibits cAMP production, but does not induce apelin receptor endocytosis. These data indicate that apelin receptor signaling (coupling to Gi) and endocytosis are functionally dissociated, possibly reflecting the existence of several conformational states of this receptor, stabilized by the binding of different apelin fragments to the receptor. We then investigated the consequences for biological activity of this functional dissociation by evaluating the effects of various apelin fragments, injected iv, on arterial blood pressure in normotensive Wistar Kyoto rats. We showed that apelin fragments, that did not induce receptor internalization in vitro but kept their ability to activate receptor coupling to Gi, did not decrease arterial blood pressure. Our data showed that hypotensive actions of apelin peptides correlate with the ability of those ligands to internalize. Thus, the depressor response of apelin may be controlled by apelin receptor endocytosis, which is probably required for initiation of a second wave of signal transduction. The development of biaised agonists of the apelin receptor capable of promoting only one specific signal transduction pathway may therefore offer new therapeutic avenues for the treatment of cardiovascular disorders.
Collapse
|
23
|
Laurent S, Fassot C, Lacolley P, Boutouyrie P. 14.01 MOLECULAR DETERMINANTS OF ARTERIAL STIFFNESS. Artery Res 2007. [DOI: 10.1016/s1872-9312(07)70023-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
24
|
Briet M, Bozec E, Laurent S, Fassot C, London GM, Jacquot C, Froissart M, Houillier P, Boutouyrie P. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 2006; 69:350-7. [PMID: 16408126 DOI: 10.1038/sj.ki.5000047] [Citation(s) in RCA: 242] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular morbidity and mortality. Arterial stiffness and remodeling have been well documented in patients with end-stage renal disease, but little is known about arterial phenotype in CKD patients with moderate reduction in glomerular filtration rate (GFR). In total, 95 patients (58+/-15 years, mean+/-s.d.) with CKD and GFR measured by renal clearance of (51)Cr-ethylenediaminetetraacetate were compared to 121 hypertensive patients without CKD (59+/-11 years), and 57 normotensive subjects (56+/-6 years). Common carotid artery diameter, intima-media thickness (IMT), distensibility, and Young's elastic modulus were noninvasively determined with a high-definition echotracking system. Patients with CKD had a significantly larger carotid internal diameter than in hypertensives and normotensives (6.32+/-1.05, 5.84+/-0.74, and 5.50+/-0.64 m x 10(-3), respectively; P<0.001), resulting in 25% and 11% increases in circumferential wall stress, respectively, since no significant difference in IMT was observed. Carotid distensibility and elastic modulus did not significantly differ between CKD and hypertensives; normotensives had significantly higher distensibility and lower elastic modulus than CKD and hypertensive patients. Carotid-femoral pulse wave velocity was significantly higher in CKD patients than in hypertensives and normotensives. In multivariate analyses either involving the entire population or restricted to CKD patients, GFR was independently and strongly related to carotid diameter and elastic modulus. Arterial enlargement and increased arterial stiffness occur in parallel with the decline in renal function in patients with mild-to-moderate CKD.
Collapse
Affiliation(s)
- M Briet
- Department of Physiology, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Bozec E, Fassot C, Tropeano AI, Boutouyrie P, Jeunemaitre X, Lacolley P, Dabire H, Laurent S. Angiotensinogen gene M235T polymorphism and reduction in wall thickness in response to antihypertensive treatment. Clin Sci (Lond) 2003; 105:637-44. [PMID: 12911327 DOI: 10.1042/cs20030156] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2003] [Revised: 07/21/2003] [Accepted: 08/12/2003] [Indexed: 11/17/2022]
Abstract
The angiotensinogen M235T polymorphism has been linked to hypertension and cardiovascular disease. Carotid intima-media thickness (IMT) is an early marker of atherosclerosis. The objectives of the present study were to determine in previously untreated essential hypertensive patients whether carotid IMT was associated with the M235T polymorphism, and to determine whether the M235T polymorphism could influence the reduction of carotid IMT by antihypertensive treatment. Common carotid artery IMT was determined with a high-definition echotracking system in 98 previously untreated hypertensive patients in a cross-sectional study. A subgroup of 56 patients was included in a randomized double-blind parallel group study comparing the effect of the angiotensin-converting-enzyme-inhibitor enalapril with that of the beta-blocker celiprolol during a 5 month period. In the cross-sectional study, a multivariate analysis showed that the M235T genotype was a significant independent determinant of carotid IMT, explaining 7% of the variance. Carotid IMT was higher in patients homozygous for the T allele than in MM patients. In the longitudinal study, the reduction in carotid IMT after antihypertensive treatment was significantly ( P <0.01) higher in patients carrying the TT genotype than in patients carrying the MM genotype, despite similar reductions in blood pressure and independently of drug type. In conclusion, these data suggest that the angiotensinogen TT genotype at position 235 is a genetic marker for early carotid atherosclerosis in a hypertensive population and its regression under antihypertensive treatment.
Collapse
Affiliation(s)
- Erwan Bozec
- Department of Pharmacology, INSERM EMI 0107, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Durier S, Fassot C, Laurent S, Boutouyrie P, Couetil JP, Fine E, Lacolley P, Dzau VJ, Pratt RE. Physiological genomics of human arteries: quantitative relationship between gene expression and arterial stiffness. Circulation 2003; 108:1845-51. [PMID: 14530203 DOI: 10.1161/01.cir.0000091407.86925.7a] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
BACKGROUND Previous genomic studies with human tissues have compared differential gene expression between 2 conditions (ie, normal versus diseased) to identify altered gene expression in a binary manner; however, a potentially more informative approach is to correlate the levels of gene expression with quantitative physiological parameters. METHODS AND RESULTS In this study, we have used this approach to examine genes whose expression correlates with arterial stiffness in human aortic specimens. Our data identify 2 distinct groups of genes, those associated with cell signaling and those associated with the mechanical regulation of vascular structure (cytoskeletal-cell membrane-extracellular matrix). Although previous studies have concentrated on the contribution of the latter group toward arterial stiffness, our data suggest that changes in expression of signaling molecules play an equally important role. Alterations in the profiles of signaling molecules could be involved in the regulation of cell cytoskeletal organization, cell-matrix interactions, or the contractile state of the cell. CONCLUSIONS Although the influence of smooth muscle contraction/relaxation on arterial stiffness could be controversial, our provocative data would suggest that further studies on this subject are indicated.
Collapse
Affiliation(s)
- Séverine Durier
- Department of Pharmacology and INSERM EMI 107, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laloux B, Boutouyrie P. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34:1203-6. [PMID: 12677025 DOI: 10.1161/01.str.0000065428.03209.64] [Citation(s) in RCA: 720] [Impact Index Per Article: 34.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
BACKGROUND AND PURPOSE Pulse pressure is a stronger predictor of cardiovascular events than systolic or diastolic blood pressure in large cohorts of French and North American patients. However, its influence on stroke is controversial. Large-artery stiffness is the main determinant of pulse pressure. The influence of arterial stiffness on the occurrence of stroke has never been demonstrated. Our aim was to establish the relationship between aortic stiffness and stroke death in hypertensive patients. METHODS We included, in a longitudinal study, 1715 essential hypertensive patients who had a measurement of arterial stiffness at entry (ie, between 1980 and 2001) and no overt cardiovascular disease or symptoms. Mean follow-up was 7.9 years. At entry, aortic stiffness was assessed from the carotid-femoral pulse wave velocity. A Cox proportional hazard regression model was used to estimate the relative risk (RR) of stroke and coronary deaths. RESULTS Mean+/-SD age at entry was 51+/-13 years. Twenty-five fatal strokes and 35 fatal coronary events occurred. Pulse wave velocity significantly predicted the occurrence of stroke death in the whole population. There was a RR increase of 1.72 (95% CI, 1.48 to 1.96; P<0.0001) for each SD increase in pulse wave velocity (4 m/s). The predictive value of pulse wave velocity remained significant (RR=1.39 [95% CI, 1.08 to 1.72]; P=0.02) after full adjustment for classic cardiovascular risk factors, including age, cholesterol, diabetes, smoking, mean blood pressure, and pulse pressure. In this population, pulse pressure significantly predicted stroke in univariate analysis, with a RR increase of 1.33 (95% CI, 1.16 to 1.51) for each 10 mm Hg of pulse pressure (P<0.0001) but not after adjustment for age (RR=1.19 [95% CI, 0.96 to 1.47]; P=0.10). CONCLUSIONS This study provides the first evidence, in a longitudinal study, that aortic stiffness is an independent predictor of fatal stroke in patients with essential hypertension.
Collapse
Affiliation(s)
- Stéphane Laurent
- Department of Pharmacology and INSERM EMI 0107, Hôpital Européen Georges Pompidou, Paris, France.
| | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
1. This study investigated the effects of blocking the AT1 angiotensin receptors with irbesartan, either peripherally or centrally, on systemic blood pressure, intracranial pressure and cerebral perfusion pressure following experimental subarachnoid haemorrhage (SAH) in urethane-anaesthetized rats. Sympathetic nervous activation was determined by measuring plasma noradrenaline levels. 2. In untreated animals, SAH induced a sustained increased in intracranial pressure from 2.1 +/- 0.3 to 16 +/- 2 mmHg (3 h, P < 0.001). Cerebral perfusion pressure was reduced by 20 % (P < 0.001), this reduction being maintained for 3 h. Sympathetic activation was evident in the high level of plasma noradrenaline measured 3 h post-SAH (751 +/- 104 vs. 405 +/- 33 pg ml(-1), P < 0.05). 3. Acute peripheral pretreatment with irbesartan (3 mg kg(-1), I.V.) prevented the rise in plasma noradrenaline and further aggravated the decrease in cerebral perfusion pressure by producing transient systemic hypotension (blood pressure was 85 +/- 6 mmHg at 2 h post-SAH vs. 100 +/- 3 mmHg, P < 0.01). 4. Intracisternal pretreatment with irbesartan (0.035 mg) did not prevent the rise in plasma noradrenaline post-SAH but enhanced the rise in intracranial pressure by 75 % compared with untreated animals. 5. This study demonstrates that peripheral endogenous angiotensin II interacts with the sympathetic nervous system in order to maintain an adequate cerebral perfusion following SAH. Endogenous angiotensin II in the brain seems to exert a protective effect by counteracting the elevation in intracranial pressure that occurs following experimental SAH.
Collapse
Affiliation(s)
- C Fassot
- INSERM E 0107, Faculté de Médecine, 15 rue de l'Ecole de Médecine, 75270 Paris Cedex 6, France
| | | | | | | |
Collapse
|
29
|
Fassot C, Lambert E, Lambert G, Friberg P, Elghozi J. Acute and chronic alterations in blood pressure variability following experimental subarachnoid haemorrhage. Regul Pept 2001; 99:31-9. [PMID: 11257312 DOI: 10.1016/s0167-0115(01)00217-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
This study examined the role of the renin-angiotensin and vasopressin systems on systolic blood pressure (SBP) variability following subarachnoid haemorrhage (SAH) in conscious rats. Animals received no treatment, the angiotensin II AT1 receptor antagonist, losartan, or the vascular vasopressin receptor antagonist, AVPX. SAH resulted in a transient sympathetic activation as estimated from the increase in the mid-frequency oscillations of SBP (3.2 +/- 0.8 mm Hg2, 3 hours after the injury vs. 1.3 +/- 0.3 mm Hg2 in control conditions, p < 0.01). On the second and fourth day following SAH, a marked elevation in the low-frequency component of SBP was observed (7.1 +/- 1.0 mm Hg2 on day 2 vs. 2.6 +/- 0.3 mm Hg2 in control conditions, p < 0.001 and 6.3 +/- 1.1 mm Hg2 on day 4 vs. 2.6 +/- 0.3 mm Hg2 in control conditions, p < 0.01). Pre-treatment with losartan prevented the acute rise in the mid-frequency oscillations in SBP and partially reduced the low-frequency component observed at 2 and 4 days. Administration of AVPX on the second and fourth day following SAH normalised the elevated low-frequency oscillations in SBP. This study indicates that the modifications in SBP variability observed in the early and delayed stage after subarachnoid haemorrhage involve angiotensin II. Vasopressin seems to be implicated in the delayed development of low-frequency fluctuations of SBP.
Collapse
Affiliation(s)
- C Fassot
- INSERM E0107, Biomécanique et Pharmacologie de la Paroi Artérielle, 15 rue de l'école de Médecine, 75670 cedex 6, Paris, France.
| | | | | | | | | |
Collapse
|
30
|
Lambert G, Lambert E, Fassot C, Friberg P, Elghozi JL. Subarachnoid haemorrhage-induced sympathoexcitation in rats is reversed by bosentan or sodium nitroprusside. Clin Exp Pharmacol Physiol 2001; 28:200-5. [PMID: 11207676 DOI: 10.1046/j.1440-1681.2001.03427.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
1. The roles played by nitric oxide (NO) and endothelin (ET) in the genesis of sympathetic nervous activation following experimental subarachnoid haemorrhage was investigated using spectral analysis of blood pressure rhythms. 2. Subarachnoid haemorrhage was induced in conscious rats by injecting 0.3 mL homologous blood via a catheter placed along the surface of the brain and directed towards the circle of Willis. Three hours after the insult and after sympathetic activation was evident, animals received either an acute injection of the ET antagonist bosentan (5 mg/kg, i.v.; n = 7), an infusion of the NO donor sodium nitroprusside (SNP; 18 microg/h; n = 7) or no treatment (n = 7). 3. Three hours following the induction of subarachnoid haemorrhage, the mid-frequency components of systolic blood pressure were markedly elevated, indicating a pronounced sympathoexcitation. However, blood pressure and heart rate levels remained unchanged at this time. In the absence of treatment, the mid-frequency components of blood pressure remained elevated for a subsequent 2 h. Treatment with a non-hypotensive dose of SNP reversed the sympathoexcitation within 1 h. Treatment with bosentan was also effective in reducing the mid-frequency oscillations in blood pressure associated with subarachnoid haemorrhage. 4. Our results indicate that subarachnoid haemorrhage is associated with an acute activation of the sympathetic nervous system. The degree of sympathoexcitation can be reversed by the use of either bosentan or SNP.
Collapse
Affiliation(s)
- G Lambert
- Laboratoire de Pharmacologie, CNRS UMR 8604, Faculté de Médecine Necker, Paris, France.
| | | | | | | | | |
Collapse
|
31
|
Lambert E, Lambert G, Fassot C, Friberg P, Elghozi JL. Subarachnoid hemorrhage induced sympathoexcitation arises due to changes in endothelin and/or nitric oxide activity. Cardiovasc Res 2000; 45:1046-53. [PMID: 10728431 DOI: 10.1016/s0008-6363(99)00416-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
OBJECTIVE The demonstration of the effectiveness of endothelin antagonists and nitric oxide donors in managing vasospasm following subarachnoid hemorrhage is encouraging. Whether such drugs can modify the sympathoexcitation that accompanies this condition remains unknown and was the basis for the present report. METHODS Subarachnoid hemorrhage was induced in conscious rats by injecting blood via a catheter placed along the surface of the brain and directed towards the circle of Willis. We combined measurements of arterial plasma catecholamines with the spectral analysis of blood pressure variability in order to examine sympathetic nervous activation following subarachnoid hemorrhage. Experiments were performed in untreated animals and in rats following pretreatment with either bosentan or sodium nitroprusside. RESULTS Indicative of a pronounced sympathoexcitation, the 0.2-0.6 Hz frequency components of blood pressure were markedly elevated following subarachnoid hemorrhage (2.5 +/- 0.5 vs. 8.9 +/- 2.6 mmHg2, P < 0.01). Parallel changes in plasma norepinephrine concentration were observed (1.0 +/- 0.2 vs. 2.4 +/- 0.4 nmol/l, P < 0.01). The subarachnoid injection of saline did not modify blood pressure variability or plasma norepinephrine concentrations. Pretreatment with either bosentan or sodium nitroprusside completely prevented the subarachnoid hemorrhage induced sympathoexcitation. CONCLUSIONS Experimental subarachnoid hemorrhage is associated with a pronounced activation of the sympathetic nervous system. It would appear that this sympathoexcitation has its roots ensconced in either the release of endothelin or an impairment in nitric oxide mediated vasodilation.
Collapse
Affiliation(s)
- E Lambert
- Laboratoire de Pharmacologie, CNRS UMR 8604, Faculté de Médecine Necker, Paris, France.
| | | | | | | | | |
Collapse
|
32
|
Fassot C, Lambert G, Gaudet-Lambert E, Friberg P, Elghozi JL. Beneficial effect of renin-angiotensin system for maintaining blood pressure control following subarachnoid haemorrhage. Brain Res Bull 1999; 50:127-32. [PMID: 10535331 DOI: 10.1016/s0361-9230(99)00089-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Subarachnoid haemorrhage is a serious condition often accompanied by delayed cerebral ischaemia. Earlier reports have provided evidence suggesting a role for angiotensin II in the development of cerebral vasospasm following subarachnoid bleeding. We sought to examine the influence of angiotensin II blockade with losartan on blood pressure and survival in animals following experimental subarachnoid haemorrhage, induced in conscious rats by injecting homologous blood via a catheter placed along the surface of the brain. We combined measurements of plasma renin activity with blood pressure recording in order to examine renin-angiotensin system activation following experimental subarachnoid haemorrhage. Following subarachnoid injury an approximately three-fold increase in plasma renin activity occurred (3.4 +/- 1.0 vs. 10.1 +/- 1.8 ng angiotensin I produced/ml/h, p < 0.01). In animals treated with losartan (20 mg/kg) prior to the induction of subarachnoid haemorrhage blood pressure fell dramatically following the cerebral injury (124 +/- 5 vs. 94 +/- 7 mmHg, p < 0.001), whereas blood pressure remained unchanged in control animals. Survival was markedly reduced in those animals treated with losartan. Given the pronounced decrease in blood pressure and impaired survival following subarachnoid haemorrhage in animals treated with losartan, it would appear that the acute activation of the renin-angiotensin system following this insult is in fact a desirable, compensatory response.
Collapse
Affiliation(s)
- C Fassot
- Laboratoire de Pharmacologie, CNRS UMR 8604, Faculté de Médecine Necker, Paris, France.
| | | | | | | | | |
Collapse
|
33
|
Faivre-Fiorina B, Caron A, Fassot C, Fries I, Menu P, Labrude P, Vigneron C. Presence of hemoglobin inside aortic endothelial cells after cell-free hemoglobin administration in guinea pigs. Am J Physiol 1999; 276:H766-70. [PMID: 9950880 DOI: 10.1152/ajpheart.1999.276.2.h766] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The endothelium is the production site of several potent vasoactive factors that contribute to the modulation of the vascular tone. Because hemoglobin-based oxygen carriers (HBOC) have been demonstrated to cause vasoconstriction and thereby increase arterial pressure by interacting with endothelium-derived factors such as nitric oxide and endothelin-1, we hypothesized that hemoglobin could penetrate into the endothelial cells. Therefore, we investigated the presence of hemoglobin into guinea pig aortic endothelial cells by immunohistochemical staining after exchange transfusion with a hemoglobin-based oxygen carrier. Despite the large molecular size of HBOC due to chemical modifications designed to prevent hemoglobin subunit dissociation and extravascular leakage, hemoglobin was detectable by immunohistochemical staining into the endothelial cells. These findings suggest that the vascular endothelial cells could uptake hemoglobin by endocytosis mechanisms or could help hemoglobin to cross the endothelial barrier toward media by transcytosis mechanisms. These findings are very important to lead future investigations to the mechanisms by which HBOC cause vasoconstriction.
Collapse
Affiliation(s)
- B Faivre-Fiorina
- Laboratoire d'Hématologie-Physiologie, Faculté de Pharmacie, Université Henri Poincaré-Nancy 1, F-54001 Nancy Cedex, France
| | | | | | | | | | | | | |
Collapse
|